OSI-906 (Not yet branded)
Other Medications
Description
OSI-906 (linsitinib) is an oral dual inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) that was developed for treatment of various solid tumors including colorectal cancer. The compound targets the IGF/insulin signaling pathway, which plays a role in cancer cell proliferation and survival. In colorectal cancer, OSI-906 has been evaluated as monotherapy with continuous or intermittent dosing schedules, and in combination with everolimus for patients with refractory metastatic disease.
Mechanism of Action
OSI-906 functions by competitively binding to and inhibiting both IGF-1R and IR tyrosine kinases, blocking downstream signaling through the PI3K/AKT and MAPK pathways. This dual inhibition disrupts cancer cell growth, survival signals, and metabolic processes that tumor cells depend on for progression and metastasis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.